SENSITIVITY OF PRO'S TO DETECT CHANGES IN QUALITY OF LIFE IN PATIENTS TREATED WITH A BIOLOGIC AGENT
Author(s)
Pumford N1, Wade A1, Crawford G1, McConnachie A21Patients Direct, Glasgow, United Kingdom, 2Glasgow University, Glasgow, United Kingdom
Presentation Documents
OBJECTIVES: To investigate whether patient reported outcomes in patients who had been prescribed etanercept , an anti –TNF inhibitor, by their specialist could detect changes in quality of life over time. A longitudinal evaluation was designed to collect naturalistic data about their condition, medications and health care experience. METHODS: The evaluation was conducted throughout the United Kingdom using a web-based system supplemented by telephone reporting PROBE (patient reported outcomes based evaluation). Outcome measures included demographic data, the condition, previous treatment, current medications, patients’ experiences of their condition, treatment and healthcare and quality of life. RESULTS: A total of 344 people participated in the evaluation at baseline, 290 online and 54 by telephone with a mean age of 53 years and 62% female. 191 of these patients had Rheumatoid Arthritis, 44 Psoriatic Arthritis, 43 Ankylosing Spondylitis, 35 psoriasis and 31 other/ missing data. Patients were severely affected by their condition as noted on their quality of life measures at baseline. Treatment had a marked beneficial effect for patients as recorded by all measurement tools. All scores given in order. Baseline month 6 mean (SD) clinical global impression 1 worst health 7 best health 3.15 (1.09) to 4.31 (1.50) p<0.001. EQ 5D Questionnaire 0.0 worst health 1.0 best health 0.39 (0.34) to 0.64 (0.27) p<0.001. DLQI 30 worst effect 0 no effect on life 14.57 (6.74) to 3.69 (6.14) p<0.001. HAQ. 0 no difficulty 3 unable to perform action 1.77 (0.63) to 1.25 (0.73) p<0.001. CONCLUSIONS: This evaluation shows that patients have significant impairment of their quality of life before commencing a biologic agent across a range of conditions. Treatment with the biologic agent showed a sustained improvement in their quality of life up to 6 months. The PROBE methodology (web-based system supplemented by telephone reporting) successfully captured changes in patient reported quality of life measures.
Conference/Value in Health Info
2011-11, ISPOR Europe 2011, Madrid, Spain
Value in Health, Vol. 14, No. 7 (November 2011)
Code
PMS64
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Musculoskeletal Disorders, Sensory System Disorders